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In this study we investigated if smoking subjects with a normal or slightly decreased lung function dier in the
lymphocyte pattern compared to never-smokers.
In a group of ‘healthy’ smokers (n=58) and never-smokers (n=34) 60 years old, we investigated the lymphocyte
pattern in both BAL (n=30 and n=18 respectively), bronchial epithelium and lamina propria (n=14 and n=10
respectively) and blood.
We found that all subjects, despite smoking history, had a higher number of CD8+ cells per mm2 in the
epithelium compared to the lamina propria in the bronchial biopsies. In smokers, these CD8+ cells were
significantly negatively correlated to FEV1 (r=7056, P=004). In smokers, the number of CD8+ lymphocytes
was higher and the T cell activation markers (CD57+ and CD28+) were lower in BAL, than in never-smokers.
This last finding was also seen in blood for CD3+57+.
We conclude, that in ‘healthy’ smokers the lymphocyte patterns are dierent compared to never-smokers, to
some extent in BAL. There is also a relation between lymphocytes in the bronchial mucosa and lung function. This
has previously been shown in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis
but not in asymptomatic smokers.
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About 50% of all smokers acquire chronic bronchitis, and
at least 15% develop chronic obstructive pulmonary disease
(COPD) (1, 2), and the prevalence is increasing (3).
However, there are no good indicators for an early
identification of subjects who will later develop sympto-
matic COPD. Therefore, we wanted to investigate if there is
any lymphocyte marker in smokers with decreased lung
function that separates them from smokers with normal
lung function.Received 11 October 1999 and accepted 26 October 1999.
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0954-6111/00/030264+09 $35?00/0It is known that lymphocytes infiltrate the bronchial
mucosa in chronic bronchitis (4). It has been possible to
study the subpopulations of the lymphocytes (5) with
immunohistochemistry. From a previous study (6), it is
known that the lymphocytes in the bronchial mucosa in
man are mainly T cells. We have shown that the
lymphocytes seem to be concentrated in the epithelial layer
(7). Most probably, these lymphocytes are recruited from
blood upon activation, and migrate through the mucosa to
be accumulated in the bronchoalveolar space (7). In two
recent biopsy studies (8,9), concentrating on investigating
the lymphocyte subpopulations in lamina propria, exclud-
ing the epithelium, a correlation between lung function and
biopsy findings have been described. Di Stefano and
colleagues (8) showed that smokers with chronic bronchitis
and COPD have significantly more CD3+cells in the
lamina propria than smokers with chronic bronchitis
without obstruction. There was also a trend towards higher
values of CD4+ and CD8+cells in patients with chronic# 2000 HARCOURT PUBLISHERS LTD
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between CD3 and FEV1 was found in the smoking group.
O’Shaughnessy et al. (9) described a negative and sig-
nificant correlation between CD8+cells in lamina propria
and FEV1 in smoking subjects.
There are some studies where the lymphocyte subpopula-
tions in BAL and blood have been described (10–13). Most
of these studies, dealing with smoking and lymphocytes,
have investigated the subpopulation pattern in patients
with chronic bronchitis with or without COPD.
Our hypothesis was that smokers with normal or slightly
decreased lung function have a dierent lymphocyte pattern
in both the bronchial mucosa, BAL and blood compared to
never-smokers with normal lung function. These lympho-
cyte subpopulation patterns might distinguish smokers who
will develop COPD from those that will stay ‘healthy’.
To test our hypotheses we investigated a group of
‘healthy’ smokers, i.e. smokers that had not sought medical
attention due to respiratory diesease earlier, and a group of
never-smokers. The men were investigated with spirometry
and bronchoscopy, during which bronchial biopsies were
taken and a bronchoalveolar lavage (BAL) was performed.
Materials and methods
The subjects were recruited from the population study ‘Men
born 1933 in Go¨teborg’ (14), a random half of all men born
in 1933 and resident in Go¨teborg in 1983 (n=1016). Eight
hundred and seventy-nine men of the original cohort, who
were still alive and living in Go¨teborg were recruited for a
second examination, in 1993. Of the 602 participating men,
532 were evaluated with spirometry. Of these men, 112 were
smokers, 198 were never-smokers and 222 were former
smokers of more than a month’s duration. All smokers and
a random sample of 60 lifelong never-smokers were invited
to an examination of their lungs. Fifty-eight smokers and
34 never-smokers consented to further investigations, and
of these 30 smoking and 18 never-smoking men accepted to
undergo a bronchoscopy.
Subjects were excluded if they: (i) had any airway disease
for which they had sought medical attention (n=11), (ii)
had scoliosis or other diseases with deformation of thorax
(n=0), (iii) had a history of congestive heart failure or
unstable angina pectoris (n=4) or (iv) any other severe
disease (n=5); (v) if they had had any kind of infection
during the 4 weeks preceeding the examination (n=0); or
(vi) if they were on corticosteroid treatment (n=0), N-
Acetylcysteine (NAC) (n=0) or acetylsalicylic acid (ASA)
(n=0) treatment less than 4 weeks prior to blood tests or
bronchoscopy, except in those subjects on ASA treatment
due to a prior heart infarction (n=8). Four smokers had
quit smoking before they came to the follow-up and were
therefore excluded. The rest of the drop-outs were not
willing to take part in the study for dierent reasons. The
drop-out frequency was equally distributed in smokers and
never-smokers.
Thirty-three of 58 (57%) were heavy smokers ( 15
cigarettes per day) and 25/58 (43%) were light smokers(515 cigarettes per day). The median number of pack-years
was 35 (9–79) years.
The study was approved by the local Ethics Commitee at
Sahlgrenska University Hospital, Go¨teborg Sweden.
FIBEROPTIC BRONCHOSCOPY AND
SAMPLE COLLECTIONS:
Premedication was given with diazepam 5 mg orally
followed by 05 ml morphine-scopolamin intramuscularly.
If the person had a history of kidney or gall bladder disease,
petidine, 75 mg intramuscularly and atropine 0.5 mg sub-
cutaneously were given instead of morphine-scopolamin.
Additional diazepam (25–5 mg) intravenousely was also
given during the bronchoscopic procedure in some cases.
All persons were given terbutalin 025 mg doseÿ1 2 3 in a
nebulizer to avoid unexpected bronchoconstriction during
the procedure. Local anaesthesia was given initially with
1% tetracaine-spray in the mouth and laryngeal tract.
Additional anaesthesia was applied through the broncho-
scope channel for the lower respiratory tract. The
bronchoscopy was performed transorally with an Olympus
flexible fiberoptic bronchoscope. The subjects were exam-
ined in a supine position by one experienced bronchoscopist
(AEJ). Another experienced bronchoscopist (CGL) exam-
ined two subjects. Oxygen saturation was measured with an
Ohmeda Pulse Oximeter during the bronchoscopy and
supplemental oxygen was given at a rate of 2–3 l minÿ1
through a nasal catheter when needed.
All samples were collected between 8.30 and 10.00 h
Bronchoalveolar lavage (BAL) was performed as follows.
Three  50 ml of phosphate buered saline (PBS) was
instilled through the bronchoscope channel into the middle
lobe with the bronchoscope in a wedged position, and
suction was done after each portion of PBS into siliconized
bottles placed on ice. The samples were then transported to
the laboratory for analysis. BAL was performed during all
bronchoscopies but in 11 out of 30 smokers and in one out
of 18 never-smokers the BAL could not be evaluated due to
debris and dead cells that made the flow cytometry analysis
impossible to interpret. Cell recovery and viability has been
published earlier (Table 1).
Peripheral bronchial biopsies (three to four biopsies per
subject) were also taken with an alligator forceps from the
subsegmental septa in the lower left lobe. The biopsies were
gently removed from the forceps and immediately placed in
a sterile and moistened chamber and were transported to
the laboratory for further processing. Fourteen out of 30
biopsies from the smokers and 10 out of 18 biopsies from
the never-smokers were evaluable. The reason for this was
that in five out of 30 smokers and in one out of 18 never-
smokers, no biopsy material was obtainable. In 11 out of
the remaining 25 smokers and seven out of the remaining 17
never-smokers no histologically evaluable biopsy material
was obtained. Two more biopsies in each group, did not
give an adequate CD69 staining in the epithelium, and the
results from both the epithelium and lamina propria were
therefore excluded. These subjects, not analysed with
immunohistochemistry, did not dier in sex, age or lung
TABLE 1. Recovery and cell viability in BAL. Cell populations in BAL and bronchial lavage
Smokers Never-smokers P
(n=30) (n=17)
Total number of cells in BAL (106) 152 (05–48) 85 (02–18) n.s.
Cellkoncentration in BAL (104cells mlÿ1) 231 (12–685) 92 (25–200) 0002
Recovery in BAL (ml) 64 (30–110) 89 (50–120) 00003
Cell viability in BAL (alive/dead, %) 68 (42–88) 74 (43–86) n.s.
Cell dierential counts—BAL (%)
Macrophages 93 (39–99) 87 (75–96) 500001
Lymphocytes 1 (0–5) 10 (0–23) 500001
Neutrophils 2 (0–11) 2 (1–5) n.s.
Eosinophils 04 (0–2) 08 (0–3) n.s.
Cell dierential counts—bronchial lavage (%)
Macrophages 14 (0–69) 17 (3–45) n.s.
Lymphocytes 02 (0–1) 01 (0–1) n.s.
Neutrophils 40 (1–87) 19 (1–79) 001
Eosinophils 1 (0–10) 04 (0–4) n.s.
Mean and range values are presented, n = number of subjects, P = Mann–Whitney’s significance U-test.
TABLE 2. Lung function in subjects with/without biopsy analysis
Evaluable biopsies Not evaluable or no biopsies P
Smokers (n=14) (n=16)
TLC (% pred.) 9414 10013 n.s.
RV (% pred.) 10532 12629 n.s.
VC (% pred.) 8713 8710 n.s.
FEV1 (% pred.) 9418 9010 n.s.
DLCO (% pred.) 8014 8718 n.s.
DLCO / VA (% pred.) 8218 8517 n.s.
N2-test (% pred.) 17673 19975 n.s.
Never-smokers (n=10) (n=8)
TLC (% pred.) 9813 9812 n.s.
RV (% pred.) 10236 8610 n.s.
VC (% pred.) 929 10214 n.s.
FEV1 (% pred.) 1059 11419 n.s.
DLCO (% pred.) 8812 10714 0.01
DLCO / VA (% pred.) 887 9714 n.s.
N2-test (% pred.) 10847 7230 n.s.
n=number of subjects, meanSD, P according to Mann–Whitney’s U-test.
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pred.)] in never-smokers compared to those evaluated
(Table 2).
IMMUNOHISTOCHEMISTRY
Biopsies were oriented using a dissection microscope in
order to obtain perpendicular sections including both
epithelium and lamina propria. They were then embedded
in Tissue Tek II OCT (Miles Scientific, Naperville, IL,
U.S.A.), immediately frozen in isopenthane precooled inliquid nitrogen, and stored at ÿ708C. The biopsies were cut
with a cryostat ( Kryostat 1720 Digital, Leitz, Germany )
into 5 mm sections and placed on gelatin coated slides. One
section from each biopsy was fixed in formalin alcohol and
was stained by Mayer’s haematoxylin, lithiumcarbonate
and eosin. Only biopsies with intact epithelium and lamina
propria were subject to immunohistochemistry. Five sec-
tions were taken 30–40 mm apart and were put on a gelatin
coated slide for each staining. The sections were stored at
ÿ208C before immunohistochemistry staining was per-
formed.
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the optimal dilutions of reagents were determined using
bronchial and tonsil tissue, as well as phythaemagglutinin
(PHA)-stimulated blood lymphocytes. Briefly, the sections
were brought to room temperature, fixed in acetone and air
dried. Sections were rehydrated in PBS and incubated with
the primary antibody. The following primary monoclonal
antibodies and concentrations were used: CD3 (2.1 mg/ml),
CD4 (1.7 mg/ml), CD8 (1 mg/ml) (DAKOPATTS A/S,
Glostrup, Denmark) and CD69 (0.67 mg/ml, Caltag La-
boratories, San Fransisco, CA, U.S.A.). After incubation
for 1 h at room temperature and washing three times in
PBS, the slides were further processed in an automatic
staining machine (Cadenza; Shandon Scientific Ltd, Che-
shire, U.K.). After washing in PBS, the slides were
incubated for 1 h at room temperature with a biotinylated
rabbit anti-mouse immunoglobulin antibody (Fab E413,
4 mg/ml, DAKOPATTS A/S ) diluted in PBS with 1%
bovine serum albumin (BSA) (Sigma, St.Louis, MO,
U.S.A.) and 1% human serum. After another washing in
PBS, endogenous peroxidase activity was blocked with
0.3% H2O2 (E. Merck, Darmstadt, Germany) in PBS for
5 min in the dark. After washing in PBS, the slides were
incubated with streptABComplex/HRP Duet (DAKO-
PATTS A/S) for 1 h. After a final wash in PBS, 3-amino-
9-ethylcarbazole (AEC, Sigma), 33 mg/ml diluted in 0.02M
sodium acetate buer (E.Merck), pH 5.5, with 12%
dimethylsulphoxide (DMSO) and 0.5% H2O2 was added
as substrate. The reaction was stopped after 8–15 min with
distilled water for optimal colour and development.
Counterstaining was performed with Mayer’s haematox-
ylin. The slides were mounted in an aquous medium
(Aquatex, E. Merck).
The number of positive cell profiles per mm2 in each
section was determined using a light microscope (Axioplan,
Carl Zeiss Jena GmgH, Jena Germany) connected to a
digital camera (Prog/Res 3012, Kontron Elektronik
GmbH, Eching, Germany) connected to a computer
(Kontron Elektronik GmbH). Cell profiles per mm2 was
estimated using an interactive image analysis system (IBAS
version 2.5, Kontron Elektronik GmbH). Object magnifi-
cation was 40.
The sections were analysed separately in the epithelial
and the lamina propria compartments. In the epithelial
compartment the whole available area and in the lamina
propria compartment the area between 0 and 100 mm below
the basement membrane was analysed. Lymphocytes were
counted as positive if they had a nuclear profile surrounded
by a distinctly coloured cell membrane. Lymphocytes with
only segments of a membrane were not counted and
membranes without a nuclear profile were excluded.
FLOW CYTOMETRY
Subpopulations of lymphocytes in BAL and blood were
determined by flow cytometry. The samples were stained
with combinations of murine monoclonal antibodies,
directly conjugated with fluorochromes (fluorescein iso-
thiocyanate, phycoerythrine or Per-CP) or with a biotin-conjugated antibody and streptavidin conjugated with Per-
CP. BAL cells (1 105 cells/sample) and whole blood (with
EDTA as anticoagulant and in a volume corresponding to
about 5 105 cells/sample) were incubated at 48C for
15 min with antibodies in the concentrations recommended
by the manufacturer.
The following fluorescein isothiocyanate-conjugated
antibodies were used: CD4, CD25, CD44, CD45RA,
CD69, TCRab (Becton-Dickinson Inc., Mountain View,
CA, U.S.A.); CD26 ( Coulter Co, Miami, FL, U.S.A.);
CD29 (DAKOPATTS A/S); CD49a and TCR gd (T Cell
Diagnostics Inc., Cambridge, MA, U.S.A.). The following
phycoerythrin-conjugated antibodies were used: CD8,
CD25, CD28, CD38, CD45RO, CD54, CD56+ CD16,
HLA-DR and 62L (Becton-Dickinson Inc.). The following
Per-CP-conjugated antibodies were used: CD3, CD4 and
CD19, and Per-CP-conjugated streptavidin (Becton-Dick-
inson Inc.). The following biotinylated antibody was used :
CD57 (Becton-Dickinson Inc.). Cell analysis was done on a
fluorescence activated cell sorter (FACScan) flow cytometer
(Becton-Dickinson Inc.), calibrated with CALIBRITETM
beads (Becton-Dickinson Inc.) and AutoCOMPTM soft-
ware ( Becton-Dickinson Inc.). A lymphocyte gate was set
manually according to the location in the forward scatter
vs. side scatter diagram. Negative isotype controls (Becton-
Dickinson Inc.) were used to set quadrant markers which
delineated positive fluorescent staining from background
staining. Dot plots and quadrant statistics from three-
colour analysis were generated by Lysis II software
(Becton-Dickinson Inc.). The absolute number of blood
lymphocytes was determined using a haematological cell
counter (Sysmex-K1000; TOA Medical Electronics Co,
Japan). In a majority of the BAL samples it was dificult to
discriminate events representing lymphocytes from events
due to debris in the forward scatter vs. side scatter diagram.
To compensate for this, all percentages of lymphocyte
subpopulations from BAL and blood from each individual
were divided by the percentages of cells positive for CD45
and negative for CD14, which represent all major
lymphocyte populations. These adjusted values were then
used in all calculations. Results for each subpopulation was
expressed in BAL as percentage of lymphocytes or
percentage of T lymphocytes and in blood as number of
cells 6109 l
ÿ1
.
LUNG FUNCTION TESTS
All subjects had their lung function tested with lung
volumes, spirometry, diusion capacity test and N2-test.
Lung volumes were obtained by a flow displacement body
pletysmograph (SensoriMedics 2200, Bilthoven, The Neth-
erlands). Forced expired volume in 1 sec (FEV1) and vital
capacity (VC) were obtained on a water sealed regularly
calibrated bell spirometer. Carbon monoxide transfer
(DLCO) was assessed by the single breath method with
standard equipment (SensorMedics 2200). The slope of
phase III was obtained by the single breath N2 method (15).
FIG. 1. The relationship between CD8+ cells in the
lamina propria compartment (SE) and FEV1 (% pred.) in
(n=14.)
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Coal and Steel Community (ECSC) reference values (16)
and for DLCO and DLCO/VA we used the reference values
according to Salorinne (17). For single breath N2-test we
used our own data, from earlier studies (18).
STATISTICAL METHODS
As data for lymphocyte subpopulations are not normally
distributed, group data are presented with their median and
range. For lung function variables, mean and standard
deviation (SD) are presented. The Mann–Whitney U-test is
used for the comparison between smokers and never-
smokers. For correlations between lung function and
lymphocyte subpopulations, Spearman Rank correlation
test has been used. We used Stat View 451 as a statistical
package.
Results
LYMPHOCYTES IN BRONCHIAL BIOPSIES
IN SMOKING AND NEVER-SMOKING MEN
Comparison between the epithelial compartment
and lamina proria
Significantly higher median numbers of CD8+cells in the
epithelial compared to the lamina propria compartment
(Table 3) was found, in both smokers (P5 001) and never-
smokers (P 5 005).
Also, significantly higher median numbers of CD8+
compared to CD4+ T cells was seen in the epithelial
compartment (Table 3) in both groups (smokers; P5 0001
and never-smokers, P 5 005).
Comparison of bronchial biopsy findings between
smoking and never-smoking subjects
There was no significant dierence between smokers and
never-smokers concerning CD3+, CD4+, CD8+or
CD69+ cells in the epithelial or subepithelial compartment.TABLE 3. Lymphocyte subpopulations in respiratory mucosal bi
Lymphocyte subpopulations CD3+
cell-density mmÿ2 cell-d
Smokers
Epithelial (per mm2) 426 (84–911) 140
Subepithelial (per mm2) 198 (0–744) 50
Never-smokers
Epithelial (per mm2) 426 (160–1096) 217
Subepithelial (per mm2) 460 (136–977) 138
Median and range, *P50.05 and **P50.01, according to ManLymphocyte subpopulations in smokers in relation
to lung function
When lymphocyte subpopulations were correlated to
dierent lung function tests a significant negative correla-
tion between CD8+cells in lamina propria and FEV1 was
seen (r =ÿ 056, P=004) (Fig. 1). No other lymphocyte
marker was correlated to any lung function test (FEV1,
DLCO, N2)
LYMPHOCYTES IN BAL IN SMOKING AND
NEVER-SMOKING MEN
Smokers had a smaller proportion of T lymphocytes
(CD3+) than never-smokers while the proportions of B-
(CD19+) and NK- (CD3756+) cells were the same
(Table 4). Smokers also had significantly fewer T helper
(CD3+4+) cells and more cytotoxic T (CD3+8+) cells,
and thus the CD3+4/CD3+8 ratio was significantly
lower in smokers than in never-smokers. Also the T
helper memory cell (CD4+45RO+29+) proportion was
significantly lower in smokers. The activation markersopsies in smokers and never-smokers
CD4+ CD8+ CD69+
ensity mmÿ2 cell-density mmÿ2 cell-density mmÿ2
(0–384) 362 (121–700)** 95 (0–396)
(0–518) 184 (13–417) 22 (0–222)
(60–338) 518 (0–703)* 290 (16–575)
(4–5 91) 212 (6–591) 72 (1–773)
n–Whitney U-test.
TABLE 4. Comparison of lymphocyte subpopulations in BAL, in smokers and never-smokers
Never-smokers
(n=17)
Smokers
(n=19)
Cell population Surface antigen Median Range Median Range P
T lymphocyte CD3+ 89 79–97 79 55–97 0?006
B lymphocyte CD19+ 0 0–3 0 0–3 n.s.
NK cell CD3–56+ 3 0–10 2 0–10 n.s.
% of T lymphocytes
T cell receptor alfa-beta CD3+TCR alfa-beta 97 84–103 95 76–127 n.s.
T cell receptor gamma-delta CD3+TCR gamma-delta 2 0–8 6 0–25 n.s.
Unprimed cell CD3+45RA+ 29 6–57 42 0–87 n.s.
Memory cell CD3+45RO+ 96 62–107 97 52–124 n.s.
Memory helper cell CD4+ 45RO+29+ 75 33–89 46 14–92 0?009
Helper/inducer cell CD3+4+ 75 39–90 54 19–88 0?01
Cytotoxic/supressor cell CD3+8+ 21 10–59 38 10–79 0?03
CD3+4+/CD3+8+ 3?4 0?7–7?5 1?5 0?3–7?6 0?02
Activation markers CD3+DR+ 86 65–104 77 56–113 n.s.
CD3+25+ 11 0–41 20 0–91 n.s.
CD3+26+ 12 1–70 7 0–79 n.s.
CD3+28+ 75 10–95 54 24–87 0?04
CD3+38+ 17 5–55 18 5–57 n.s.
CD3+44+ 100 94–106 102 86–144 n.s.
CD3+49a+ 46 22–72 33 6–93 n.s.
CD3+54+ 82 29–100 77 29–113 n.s.
CD3+57+ 17 0–50 11 0–40 0?007
CD3+69+ 80 52–94 82 53–104 n.s.
CD3+leu8+ 18 4–56 18 1–84 n.s.
CD3+56+16+ 2 0–11 2 0–11 n.s.
Data presented as median and range, P according to Mann–Whitney U-test.
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(Table 4). There was no significant correlation between
cytotoxic T (CD3+8+) cells in BAL and FEV1 or any
other lung function test (DLCO, N2).
LYMPHOCYTES IN BLOOD IN SMOKING
AND NEVER-SMOKING MEN
Smokers had fewer NK- (CD3756+16+) cells compared
to never-smokers (Table 5) in blood. The levels of
CD3+CD4+, CD3+CD8+ cells and the CD3+4+/
CD3+8+ratio did not dier between smokers and never-
smokers in blood. The T cell activation marker CD28+
was significantly higher and CD57+ significantly lower in
blood in smokers compared to never-smokers (Table 5).
Discussion
The main findings of this study were that asymptomatic
smokers have significantly higher levels of CD8+ T
lymphocytes in BAL compared to never-smokers, and that
CD8+ T lymphocytes in the bronchial mucosa ofasymptomatic smokers, are inversely related to a decreased
lung function, FEV1. The study was performed on a group
of healthy men who were about 60 years old. The strength
of this study was that all subjects, smokers and controls,
were men born in the same year and recruited from the
same population. Previous studies on lymphocyte subpo-
pulations in bronchoalveolar lavage of healthy subjects
have been performed in young subjects (19,20). The study
was also unique because we investigated three local tissue
compartments BAL, bronchial epithelium and lamina
propria as well as blood in the same individual.
In this study, we showed that smokers had a higher
number of CD8+ lymphocytes per mm2 in the bronchial
epithelium compared to lamina propria. This was also seen
in healthy never-smokers and indicates a dierential
retention of lymphocyte subpopulations in the epithelium.
This retension occurs during migration of lymphocytes
from blood to the respiratory lumen. We did not find any
dierence between smokers and never-smokers either in the
bronchial epithelium or in the bronchial lamina propria
concerning any of the four lymphocyte markers studied
(CD3+, 4+, 8+, 69+). Saetta and di Stefano have shown
that smokers with chronic bronchitis or chronic obstructive
bronchitis have significantly higher CD3+ cells in lamina
TABLE 5. Comparison of lymphocyte subpopulations in BAL, in smokers and never-smokers
Number of lymphocytes 109 Lÿ1
Never-smokers Smokers
(n=30) (n=51)
Cell population Surface antigen Median Range Median Range P
T lymphocyte CD3+ 120 061–213 131 043–350 n.s.
B lymphocyte CD19 014 002–050 017 003–080 n.s.
NK cell CD3–56+16+ 020 006–048 015 001–055 003
T cell receptor alfa-beta CD3+TCR alfa-beta 118 052–221 123 058–330 n.s.
T cell receptor gamma-delta CD3+TCR gamma-delta 004 001–030 003 000–023 n.s.
Unprimed cell CD3+CD45RA+ 070 025–149 070 033–240 n.s.
Memory cell CD3+CD45RO+ 072 036–146 086 044–197 n.s.
Memory helper cell CD4+45RO+29+ 050 004–100 054 007–122 n.s.
Helper/inducer cell CD3+4+ 074 037–122 084 031–300 n.s.
Cytotoxic/supressor cell CD3+8+ 042 012–146 039 012–296 n.s.
CD3+4+/CD3+8+ 18 06–52 200 04–86 n.s.
Activation markers CD3+DR+ 036 004–119 029 006–158 n.s.
CD3+25+ 026 005–138 035 000–131 n.s.
CD3+26+ 002 000–065 002 000–116 n.s.
CD3+28+ 086 042–160 110 014–330 003
CD3+38+ 064 018–139 050 014–170 n.s.
CD3+44+ 118 001–221 126 013–350 n.s.
CD3+49a+ 002 000–035 003 000–038 n.s.
CD3+54+ 031 002–135 027 002–119 n.s.
CD3+57+ 032 009–078 012 003–049 00003
CD3+69+ 003 000–019 002 000–085 n.s.
CD3+leu8+ 082 009–138 085 016–285 n.s.
CD3+56+16+ 003 00–03 001 00–006 00003
Data presented as median and range, P according to Mann–Whitney U-test.
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bronchitis without airflow limitation, respectively (5,8). Di
Stefano has also shown a trend towards higher values of the
lymphocyte subpopulations CD4 and CD8 in lamina
propria in smokers with chronic bronchitis and obstructive
disease compared to smokers with chronic bronchitis alone.
Fournier et al. (6) and O’Shaughnessy (9) have both shown
significantly higher values of CD4+, CD8+ and CD8+
cells, respectively, in smokers with combined chronic
bronchitis and obstructive disease compared to non-
smokers, but they did not show any significant dierence
between never-smokers and asymptomatic smokers. The
smokers in this study were asymptomatic, which probably
explains why we did not find any dierence between
smokers and never-smokers in the bronchial biopsies.
There have been speculations that the early phase of
chronic obstructive disease are neutrophil dominated and
the later phase would be more lymphocyte dominated (21).
However, in the asymptomatic smokers in this study, we
found a significant negative correlation between the number
of CD8+ lymphocytes per mm2 in lamina proria and lung
function, measured as FEV1. Similar results have beenshown in two earlier studies in patients with chronic
bronchitis (9,22). Our present study showed the same
correlation in individuals who had not sought medical
attention due to pulmonary problems and only had an
FEV1 that was marginally aected. Therefore it seems
probable that this phenomenon also occurs early in the
development of a decrease in FEV1. Thus, we hypothesized
that there is a gradation with higher CD8+ cells leading to
a more pronounced decrease in FEV1, COPD. Our findings
with elevated levels of lymphocytes in asymptomatic
smokers contradicts the hypothesis of a mainly neutrophil
dominated early phase of COPD. It is surprising that
biopsies taken in the central airways show this dierence, as
COPD is a disese regarded to aect the small airways.
However, Saetta et al. (22) have shown that bronchial
biopsies, taken by fibre bronchoscopy that would represent
more central airways, reflect the pathology of more
peripheral airways, in this respect.
The frequency of the T cell activation marker CD57+
was lower in BAL and blood from smokers compared to
never-smokers. One possible mechanism could be a
systemic eect of smoking itself on the number of
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in the bronchial mucosa in smokers could also be of
importance. CD3+57+ lymphocytes have been shown to
contain suppressive CD8+57+ T lymphocytes that in
certain situations can downregulate other lymphocytes,
both antigen specific and non-specific (23–27). It is possible
that the lower frequency of these cells could result in an
increase in cell activation and inflammation locally in the
respiratory tract.
Another interesting finding was that the frequency of the
T cell activation marker CD28+ was lower in BAL and
higher in blood from smokers compared to never-smokers.
CD28 is a structure on T lymphocytes that binds to a B7
molecule on an antigen presenting cell during T lymphocyte
activation. The binding generates a co-stimulatory signal
necessary to generate activated lymphocytes (i.e. memory
lymphocytes). It is possible that in smokers the migration of
CD3+28+ lymphocytes over the respiratory mucosa is
reduced. Possible mechanisms could be a reduced local
production of chemotactic factors or an upregulation of
adhesion molecules in the epithelium and/or lamina proria
resulting in a reduction of the number of CD3+28+lym-
phocytes in the respiratory tract lumen. This in turn might
give a lower frequency of memory T lymphocytes in BAL.
Our finding of a lower frequency of memory helper T
lymphocytes in BAL from smokers supports this hypoth-
esis.
We also confirmed earlier findings of lower frequencies of
T lymphocytes, T helper lymphocytes, NK cells and a
decreased CD4/CD8 ratio in BAL from smokers as
compared to never-smokers (12,28). A decreased CD4/
CD8 ratio in BAL in asymptomatic tobacco-smoking
subjects has also been shown by Costabel et al. (10). The
dierence between smokers and never-smokers for
CD3+56+16+ in blood was significant, but regarded as
biologically irrelevant, as the number of cells in both
patient groups were very low.
This study shows that CD8+ cells dominate both in the
bronchial mucosa as well as in BAL in ‘healthy’ smokers.
Even though these smokers considered themselves as
healthy they had an accumulation of cytotoxic T cells,
CD8+ lymphocytes, in the bronchial mucosa more
exaggerated in smokers with some aection on FEV1. This
phenomenon has also been reported by other investigators
in patients with chronic obstructive bronchitis (9,22).
However, a relation could not be found between cytotoxic
T (CD8+) cells in BAL and FEV1.
It is possible that the CD8+ lymphocytes are regulatory
cells aecting tissue remodelling and leading to airway
obstruction. Most probably tobacco smoke is involved in
the accumulation of CD8+lymphocytes in bronchial
mucosa and BAL. In a recent study from Mattoli (29),
they showed in T lymphocyte cloning experiments that
patients with chronic obstructive bronchitis have a dierent
kind of CD8+ T cells than smokers without chronic
obstructive bronchitis. Their CD8+ T cells show a switch
from a T helper (Th) 1 to a T helper (Th) 2 cytokine
pattern. Cytotoxic CD8+ T lymphocytes with a Th1
phenotype represent a major defence against pathogens by
production of interferon-r and by cytolytic activity.Smokers with a predominance of CD8+ T cells of the
Th2 phenotype have a reduced production of interferon-r,
which normally facilitates the elimination of pathogens
(30). This may lead to chronic antigen persistence that will
result in chronic inflammation. These CD8+ T cells with
Th2 phenotype release IL-4, which is important for
antibody production. However, they might also down-
regulate some steps of cell-mediated responses that are
required for host protection (30). In one study on
transgenic mice, IL-4 was involved in enhanced mucus
glycoprotein synthesis and alteration in mucin release a
condition that may be similar to that present in smokers
with chronic bronchitis (31). These CD8+ T cells also
release IL-5, which may contribute to explain the increased
numbers of eosinophils in the bronchial tissue in patients
with chronic obstructive bronchitis and the activation of
these cells (32).
Our findings were that there were fewer memory helper T
cells and lower frequencies of some activation markers on
lymphocytes that probably are part of the defence
mechanisms in the alveolar space. These results, together
with the findings from Mattoli, may render some smokers
susceptible to the development of chronic airway inflam-
mation and progressive airflow limitation.
In conclusion, we have not succeeded in finding a single
inflammatory marker that is characteristic for smokers with
a decreased lung function. However, CD8+ T lymphocytes
seem to be of importance in our study of asymptomatic
smokers, as well as in earlier studies in patients with COPD.
Further follow-up studies will confirm if smokers with
elevated CD8+ T cells are predisposed to develop COPD.
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